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Celiac disease is an inflammatory disorder of the small intestine, triggered by the ingestion of
gluten proteins contained in wheat, barley or rye, in genetically susceptible individuals. This
disorder is considered to be mainly mediated by cellular immunity and restricted to the human
leucocyte antigen-DQ presentation of gluten-derived toxic peptides to T-cells. Moreover, the
involvement of innate immunity has been recently demonstrated to be necessary also for the
development of intestinal tissue damage. Genetic susceptibility accounts for an uncertain pro-
portion of the disease risk and gluten introduction works as the precipitating factor. However,
currently, the research interest is also focused on environmental factors and gene–environment
interactions, especially during the first months of life, which might help explain the onset of the
disease. Infectious and dietary factors that could modulate the immune response orientating it
either towards tolerance or intolerance/autoimmunity are the focus of primary attention. A
significant number of studies have looked into the protective effect of breast-feeding against the
disease. It is generally accepted that breast-feeding during the introduction of dietary gluten
and increasing the duration of breast-feeding are associated with reduced risk of developing
celiac disease. However, it is still not fully established whether breast-feeding truly protects
with permanent tolerance acquisition or only reduces the symptoms and delays the diagnosis.
Moreover, the timing and dose of gluten introduction also seem to be relevant and long-term
prospective cohort studies are being carried out in order to elucidate its role in celiac disease
development.
Celiac disease: Disease risk and prevention: Breast feeding: Gluten introduction:
Tolerance to gluten: Probiotics
Celiac disease (CD) is an inflammatory disorder affecting
primarily the small intestine and triggered by the ingestion
of gluten proteins contained in wheat, barley or rye, in
genetically susceptible individuals. It is generally accepted
that CD is a T-cell-mediated disease, in which gliadin-
derived peptides bound to human leucocyte antigen
(HLA)-DQ2 (DQA1*05/DQB1*02)/DQ8 (DQA1*0301/
DQB1*0302) molecules activate lamina propria infiltrating
T-lymphocytes. The subsequent release of pro-inflammatory
cytokines, in particular interferon (IFN)-g , leads to a pro-
found tissue remodelling, flattening of the small intestinal
mucosa and nutrient malabsorption. However, currently the
role of the innate immune response is gaining extraordinary
importance, since it seems to be involved in several ways in
the pathogenesis of the disease. Thus, it has been suggested
that innate immunity collaborates with adaptive immunity to
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induce a pro-inflammatory T-helper 1 response, to increase
the number of intraepithelial lymphocytes (IEL) and to
favour the cytolytic attack of the epithelium(1,2). CD is a
complex and multifactorial disorder in which the interplay
between environmental and genetic factors determines the
aberrant immune response to gluten proteins. The major
genetic risk factor involved in CD is represented by HLA-
DQ genes. Over 90% of CD patients express HLA-DQ2 or
in trans position in HLA-DR5/DR7 heterozygous patients.
The remaining celiac patients express DQ8(3). However,
only 3–5% subjects expressing DQ2 or DQ8 actually
develop CD and on the other hand, over 60% of familial
clustering remains unexplained by HLA genes(4), which
means that the identification of other genetic loci and
environmental risk factors is needed in order to gain new
insight into CD pathogenesis.
Wheat gliadins and other prolamines from barley and
rye are cereal storage proteins (collectively termed gluten)
unusually rich in proline and glutamine. The deamidation
of glutamine into negatively charged glutamic acid by the
enzyme transglutaminase expressed in the intestinal lamina
propria promotes the interaction of gluten-derived peptides
with the peptide pocket of HLA-DQ2/DQ8 molecules,
which can be recognized by T-cells(5,6). These gluten-
specific CD4+ T-cell clones produce IFN-g (7). However,
studies in animals have shown that mice engineered to
express human CD4 and the HLA-DR3-DQ2 haplotype(8)
or human CD4 and HLA-DQ8(9) and primed with gliadin
generate peptide-specific T-cell clones that respond to
gluten dietary exposure, but this response does not lead to
the development of enteropathy. Other transgenic mice,
expressing the human DQ8 heterodimer and mucosally
immunized with gliadin and cholera toxin as adjuvant,
were simultaneously treated intragastrically with Lacto-
bacillus casei ATCC 9595. The co-administration of
L. casei to sensitized mice enhanced the gliadin-specific
response mediated by CD4+ T-cells increasing the IFN-g
expression. However, neither the immunization with gliadin
and cholera toxin nor the addition of L. casei resulted in any
morphological alteration of the small intestinal mucosa(10).
These humanized models indicate that gluten ingestion can
be tolerated even when CD4+ T-cell immunity to gluten is
established, raising the question of the complementary
mechanisms that contribute to breaking mucosal tolerance
to gluten and turning a controlled immune response into
chronic inflammation and epithelial damage.
The role of innate immunity and viral infections in
celiac disease development
Interpretations up until the present time point to the inter-
play between adaptive and innate immune mechanisms
orchestrated by IL-15 driving IEL activation and epithelial
damage in CD pathogenesis(2). IEL (CD8+ T-cell receptor
(TCR) ab+ and TCRgd + ) are hallmarks in active CD.
While after starting a gluten-free diet numbers of CD8+
TCRab+ return to normal in parallel with villous architec-
ture recovery, TCRgd + IEL remain high for years(11,12).
These findings led to the view that CD8+ TCRab+ exert
a deleterious effect on epithelial cells that can be
antagonized by TCRgd + IEL(12). CD8+ TCRab+ are
involved in TCR-independent natural killer-like killing of
intestinal epithelial cells through binding of the natural
killer group 2D (NKG2D) receptor expressed in CD8+
lymphocytes to its ligand MHC class 1-related chain A
(MICA) in epithelial cells(1,13). Both NKG2D- and MICA-
enhanced expression in active CD might be driven by
IL-15(13,14). It has been documented that gluten toxic frag-
ments, different from those proved usual CD4+ T-cell
epitopes, induce a rapid production of IL-15 by lamina
propria macrophages and dendritic cells(15). IL-15 has also
been shown to stimulate, ex vivo, IFN-g secretion by
IEL(16). IFN-a is another cytokine that has been shown to
be up-regulated in the mucosa of active CD(17) and is a
known inducer of T-helper 1 responses. Since IFN-a and
IL-15 are key players of the early innate responses to
intracellular pathogens, the capability of infectious agents
to act as a triggering factor in the inmunopathogenic mech-
anisms leading to the breakage of tolerance to gluten has
been considered. Indeed, double-stranded RNA viruses are
strong inducers of both cytokines, which might re-instruct
or de novo recruit and activate dendritic cells to prime
gluten-specific T-cells(2). Prospective, epidemiological evi-
dence supports the role of multiple infections by rotavirus
in increasing the risk of subsequent development of celiac
autoimmunity in predisposed individuals(18) perhaps
through a disruption of the intestinal barrier and facilitation
of gliadin epitope penetration. On the other hand, in some
studies but not all, analyses of serum antibodies have
shown association between past infections with Adeno-
virus type 12 and Hepatitis C virus and the development of
CD. It has also been suggested that molecular mimicry
of viral proteins with toxic gluten peptides (homology in
amino acid sequences) might modulate the host immune
tolerance and trigger the development of CD(19,20).
Possible involvement of Toll-like receptors in the innate
and adaptive response in celiac disease
Toll-like receptors (TLR) are a class of highly conserved
membrane bound molecules which have a principal role in
the recognition of pathogenic and non-pathogenic micro-
organisms and thus act in the primary line of defence.
Dendritic cells, macrophages and epithelial cells, among
other cell types, express TLR which recognize microbial
products, such as danger signals released from micro-
organisms, as well as cell wall components, lipoproteins,
genome sequences, etc. which through its binding exert a
regulation on the activation of innate and adaptive immune
responses. The activation of TLR also directly or indirectly
influences regulatory T-cell functions(21). These findings
suggest that different TLR with different specificities and
the integration of their signals participate both in immune
activation and immune regulation. It has been suggested
that TLR might possibly be involved in the modulation of
immune responses leading to CD. The observation of
increased levels of TLR2 and TLR4 mRNA in the mucosa
of celiac patients suggests a possible inherent defect in this
branch of the innate immunity(22). Interactions with these
receptors in the surface of antigen presenting cells (APC)
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might in fact activate them and lead to the adaptive
immune response and also the breakage of self-tolerance
and the development of autoimmunity. In fact, self-reactive
antibodies from celiac patients have shown the capacity to
bind TLR4 and cause monocyte activation(20); this might
also be a consequence of molecular mimicry among harm-
ful proteins (for example from rotavirus) and self-proteins.
Dietary strategies for immunomodulation in celiac
disease pathogenesis
The protective role of breast-feeding
A systematic review and meta-analysis of observational
retrospective studies published in May 2004, concluded
that increased duration of breast-feeding is associated with
a reduced risk of CD(23). Five of the six case–control
studies that satisfied the inclusion criteria of methodologi-
cal quality found that children with CD had been breast-fed
for a significantly shorter period compared with controls.
Also, the meta-analysis of four of these studies led to the
conclusion that the risk of developing CD was significantly
reduced in children who were breast-fed at the time of
gluten introduction (OR 0.48, 95% CI 0.40, 0.59). How-
ever, from the reviewed studies it is not clear whether
breast-feeding only delays the onset of symptoms or pro-
vides a permanent protection against the disease. On the
other hand, the results of the meta-analysis are subject to
limitations, such as those derived from a recall bias that
might induce misclassification of the duration of breast-
feeding and the age of gluten introduction. Moreover,
another source of bias might be derived from sub-optimal
adjustment for potential confounders across children who
were breast-fed and those who were not. For instance, only
one of the studies controlled for the HLA genotype, which,
notably, was the one study that did not find a relationship
between breast-feeding and protection against CD. How-
ever, this was a small study with only eight cases of chil-
dren with CD and it is likely that a type II error has
occurred. Given these limitations, it seems clear that long-
term prospective cohort studies are required to investigate
further the relationship between breast-feeding and CD.
The study by Ivarsson et al.(24) is a population-based
incident case-referent study of 627 cases with confirmed
CD (reported to a CD register between November 1992
and April 1995) and 1254 referents assessing patterns of
complementary food introduction to infants. The study
revealed that the risk of CD was reduced in Swedish
children aged less than 2 years if they were still breast-fed
when dietary gluten was introduced (adjusted OR 0.59;
95% CI 0.42, 0.83) and the risk increased when the gluten
was introduced in the diet in large amounts (OR 1.5; 95%
CI 1.1, 2.1). In the present study, the effect of age at the
time of gluten introduction was not conclusive. It is bio-
logically likely that the presence of breast milk at the time
gluten is introduced increases the chance of developing
oral tolerance for the antigens of importance. It is unclear
whether this chance is only effective during a certain
period in infancy. In the present study, the exposure risk
factors explored were of no or only minor importance in
children older than 2 years. Therefore, it is also important
to pursue further whether favourable infant dietary patterns
postpone the onset of the disease or in fact reduce the
overall lifetime risk of the disease(24).
Previous to this analysis of risk factors, the authors had
documented an epidemic of symptomatic CD between 1984
and 1996 in Swedish children below 2 years of age, partially
explained by changes in infant feeding(25). The increase in
incidence was preceded by an increase in the amount of
gluten consumed and by a postponement of dietary gluten
introduction which should have resulted in a higher pro-
portion of children introduced to large amounts of gluten
after the discontinuation of breast-feeding. Recently, a
Swedish study on the prevalence in children born in 1993,
during the epidemic and under these unfavourable dietary
practices, revealed that the prevalence was as high as 3%,
3-fold higher than the usually suggested prevalence of 1%(26).
As suggested from studies showing the risk reduction
of childhood type I diabetes mellitus with breast-feeding
and late introduction of cow’s milk, it seems plausible that
in addition to the immunologically active components in
breast milk, avoidance of the early introduction of cow’s
milk protein contributes to the protective effect of breast-
feeding(27). This might as well be the case in the preven-
tion of CD by breast-feeding. Additionally, differences in
the gut microbiota between breast-fed and formula-fed
infants might account for the protection observed with
breast-feeding against the development of the disease(28).
Timing of gluten introduction
The effect of the timing of gluten introduction was studied
by Norris et al.(29). They carried out a prospective obser-
vational study from 1994 to 2004 of 1560 children at an
increased risk of CD or type I diabetes as defined by
possession of either HLA-DR3 or -DR4 alleles or having a
first-degree relative with type I diabetes. In these children,
they assessed the risk of CD autoimmunity (CDA) defined
as being positive for tissue transglutaminase autoantibody
in two or more consecutive visits. Infants exposed to
gluten in the first 3 months of life have a 5-fold increased
risk of autoimmunity compared with infants first exposed
at 4–6 months (hazard ratio 5.17, 95% CI 1.44, 18.57).
Infants introduced to gluten at 7 months or later also had
an increased risk of CDA compared with those exposed
between 4 and 6 months (hazard ratio 1.87, 95% CI 0.97,
3.00). This study did not find any evidence for a protective
effect of prolonged breast-feeding. The median duration
in both CDA positive and CDA negative children was
5 months. This analysis, however, was not restricted to the
HLA-DR3 children and possibility exists that the protec-
tive effect of breast-feeding was evident if only children
with genetic risk were considered. The different findings
between this study and others reporting a breast-feeding
protective role might be explained by the different meth-
odologies between retrospective and prospective studies
and also by the different dietary practices between Europe
and the United States(29), since in Europe the introduction
of gluten tends to occur as a replacement of breast milk at
weaning (for example, the flour-based follow-up infant
formula once used in Sweden), whereas in the United
States they appear more like two separate events. Some
Dietary strategies of immunomodulation in infants at risk for celiac disease 349
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explanations have been reported by Norris et al.(29) to the
increased risk of CDA when the first exposure to gluten
occurs in younger and older children instead of at the
age of 4–6 months. In younger children, this increased
risk would be related to the immaturity of the intestinal
epithelial barrier and, in this sense, zonulin has been
implicated as a protein released in response to gliadin,
resulting in further loss of barrier integrity as zonulin acts
to disassemble the tight junctions between enterocytes(30).
On the other hand, in children aged 7 months or older, the
factor leading to the increased risk of CDA might be the
introduction of large amounts of gluten at first exposure(29).
A recent position paper of the ESPGHAN Committee on
Nutrition has provided as possible practical suggestions on
the introduction of complementary feeding to avoid both
early (<4 months) and late (‡ 7 months) introduction of
gluten and to gradually introduce small amounts of gluten
while the infant is still breast-fed(31). This change in the
policy of complementary feeding is aimed at the modula-
tion of the predisposition of chronic disorders later in
life, particularly that of CD. This is, however, a matter of
debate, since exclusive breast-feeding for around 6 months
is considered a desirable goal both by ESPGHAN(32) and
WHO in order to support healthy growth and development
and reduce the risk of infections. As suggested by Agostoni
& Shamir(27) perhaps the 6-month theorem should be
partly revised and small amounts of solids, including
gluten, be allowed in the 4–7-month temporary window to
modulate the genetic predisposition towards an auto-
immune response, especially in developed countries where
the exposure risk to infectious agents is different from that
in the developing countries.
Is it possible to induce the acquisition of tolerance
to gluten?
Administration of antigen by the oral route induces
hyporesponsiveness to subsequent challenge with the anti-
gen given in an immunogenic form, usually by a parenteral
route, a phenomenon termed oral tolerance(33). Oral toler-
ance, however, usually affects the response of the local
immune system at the intestinal mucosa, thus, preventing
hypersensitivity reactions to food proteins that could lead
to disorders such as CD or food allergies(34). Similarly,
immunological tolerance prevents the aberrant immune
responses to commensal bacteria in the gut(33). However,
the acquisition of oral tolerance is a complex process and
is far from being fully elucidated. Works published in the
1980–1990s led to the idea that the mechanisms re-
sponsible for oral tolerance depended on the feeding
regime used, inducing tolerance leading either to clonal
anergy (or deletion) of specific T-cells or to the induction
of regulatory T-cell activity(35). More recent knowledge
has pointed at APC as fundamental players directing
tolerance or immunity towards specific antigens. It is the
level of expression of co-stimulatory molecules in APC,
such as CD80, CD86 or CD40 and the balance between
IL-12 and IL-10 produced by APC that seems to determine
whether an antigen induces tolerance of productive im-
munity when presented to a CD4 T-cell(36,37). The expres-
sion of co-stimulatory molecules in APC is controlled by
the presence of danger signals from pathogens or even by
conserved structures from any kind of microbe that are
recognized through their pattern recognition receptors,
such as TLR. Finally, current evidence suggests that
tolerance requires migration of dendritic cells that have
taken up an antigen in the mucosal lamina propria to the
mesenteric lymph nodes(38).
Several strategies aimed at down-regulation of patho-
genic T-cells by induction of Ag-specific hypo-
responsiveness have been assayed to prevent experimental
autoimmune diseases. The generation of immunological
tolerance has been attempted through ingested or inhaled
soluble proteins by the oral and the nasal routes(39). An
attempt to re-induce tolerance to gliadin has been carried
out in HLA-DQ8 transgenic mice immunized by intra-
footpad injections of gliadin in Freund’s adjuvant after
they had been previously instilled into the nostrils with
soluble gliadin following a tolerization protocol. A
decrease in systemic T-cell responses to the recombinant
a-gliadin was found as reflected by a lymphocyte pro-
liferation assay. While the immunization protocol induced
the transcription of both T-helper 1 and T-helper 2 cyto-
kines, the tolerization protocol down-regulated signifi-
cantly only the IFN-g mRNA expression(40). This finding
underlines the potential usefulness of this strategy for the
immunomodulation of this disease. However, as we have
described above, the presence of gliadin-specific T-cell
clones in transgenic mice models is not sufficient to
develop enteropathy, which makes the down-regulation of
these clones not so relevant without addressing the rest of
the pathogenic pathways involved in CD.
Primary prevention in infants at risk for celiac disease
through dietary intervention strategies
Exploring the options of primary prevention requires
combined epidemiological, clinical and basic scientific
research efforts to shed light on the potential impact of
life-style factors, genetic determinants, immunological
pathways and gene–environment interactions in the devel-
opment of CD(28). Some of the most important issues
that need investigation in CD in the coming years were
identified in 2007 by the European platform on CD
(CDEUSSA)(28). Regarding prevention, their report listed
as important issues: (1) to determine the long-term effects
of breast-feeding and the molecular basis for the protective
effect and (2) to determine the role of timing and dose of
gluten during introduction. In addition, the FISPGHAN
working group on CD added also the exploration of the
role of probiotics and prebiotics in oral tolerance(41).
In line with these priorities, several population studies
are being currently carried out to search into new strategies
for CD prevention during the first stages of life. PRE-
VENTCD is a project funded under the European Union’s
Framework Programme 6th which is being performed by
10 European countries in cooperation with the Association
of European Coeliac Societies. The project studies the
possibilities of induction of gluten tolerance in genetically
predisposed children. It is a prospective, randomized, blind
dietary intervention study in young children from high-risk
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families for CD (http://www.preventceliacdisease.com).
The idea is that introducing small amounts of gluten and
gradually increasing them during a certain window of
opportunity in the infant’s development and while being
still breast-fed will induce oral tolerance to gluten. A total
of 1000 children with a first-degree family member suf-
fering from CD will participate in this intervention study
and they will be followed during 3 years. From the fourth
to sixth month of life, they will receive a small amount of
gluten that will gradually be increased during the sixth
to ninth month, and followed by free intake thereafter.
The objective of this intervention is to decrease the inci-
dence of CD in the group receiving the gluten supplement
compared to the group receiving placebo. It will probably
be necessary to wait until the project’s ending date,
by December 2010 to know the effectiveness of these early
dietary practices as a strategy to decrease the risk of CD
development in children at risk.
The effect of environmental factors on future disease
risk is relevant at the early stages of life when the im-
mature neonate’s gut undergoes the process of microbiota
establishment and the immune system acquires full
competence and tolerance to non-harmful antigens. The
PROFICEL study, which we are currently carrying out,
together with eight Spanish hospitals and several CD
societies, is aimed at finding out environmental factors that
might be involved in the development of CD in susceptible
individuals. This study is being performed in a Spanish
sample of infants at risk for CD (at least one first-degree
relative with CD) and the global objective is to define the
combined influence of the early environmental factors
(dietary pattern and microbial exposure), the intestinal
colonization process, the genetic background and the
immune status of newborns and infants on the risk of
developing CD (http://www.proficel.es). To this end,
200 recruited infants will be prospectively studied during
at least 3 years registering early nutritional practices
and clinic history, analysing the HLA status and other
genetic markers, the immunocompetence and the intestinal
microbial colonization pattern. Preliminary analyses have
shown that an interplay exists between the HLA genes
and the microbial colonization process(42) with some bac-
terial groups, such as total Gram-negative bacteria and
Bacteroides–Prevotella, showing higher proportions in
those infants with HLA-DQ genotypes associated with a
higher risk of developing CD compared to those with
intermediate or low risk HLA-DQ genotypes. Moreover,
preliminary results on 100 infants have shown an interac-
tion between milk-feeding practices (exclusive breast-
feeding v. formula or partial breast-feeding) and HLA-DQ
genotype on the proportion and absolute counts of lym-
phocyte subsets. We have observed significant interactions
between HLA-DQ genotype and milk-feeding practices on
some of the T CD8+ lymphocyte subsets analysed, such as
memory and naı¨ve CD8+ T-cells, CD8+CD38+ , CD8+
CD28+ and CD8+CD25+ (E. Nova, T. Pozo, Y. Sanz &
A. Marcos, unpublished results). These findings might
be relevant for the future immunological response to diet-
ary gluten and merit further exploration after sufficient
follow-up of the cohort has provided information on
those children developing CD at some point. It will also
provide extremely useful information once the study of the
interaction between the microbial colonization pattern of
the intestine in infants at risk and the immunocompetence
development are analysed together as well as their possible
influence on the final outcome regarding protection or
promotion of disease development. However, the influence
of the genetic background should always be considered.
HLA susceptibility alleles for autoimmune diseases have
been suggested to interfere with the thymic development
of regulatory T cells including both CD4+CD25+ and
CD8+CD25T reg (Foxp3+ )(43,44). On the other hand, a
common genetic background (HLA and non-HLA genes)
between CD and other autoimmune conditions(45,46) and
the association of CD with other autoimmune disorders(29)
support the influence of gene–environment interactions in
the modulation of immunity and autoimmune disease risk.
Possible use of probiotics and prebiotics in infants
at risk for celiac disease
It is generally accepted that the indigenous intestinal micro-
biota are able to modulate immune responses through the
interaction with immune cells in the intestinal mucosa and to
influence immune development in newborns and infants,
while disturbances in the composition of the gut microbiota
are believed to influence the pathogenesis of allergic dis-
orders(47). On this basis, considering that alterations in the
microbiota of CD children have been documented(48), the
administration of probiotics and prebiotics seems to be a
good alternative to influence immune reactivity to gluten in
CD subjects. However, if they really have a role, then it will
more easily be exerted during the first 2 years of infancy
when the immune network is being developed. It is worth
remembering how intestinal bacteria, whether resident or
transient, beneficial or pathogenic or signalling components
derived from them, reach APC and interact with TLR
expressed in different cell types in the intestinal mucosa
with the possibility to direct immune responses and influ-
ence homeostasis. Moreover, recent studies demonstrate that
probiotics improve the epithelial barrier function in various
clinical settings. Preservation of tight junction protein ex-
pression, inhibition of epithelial apoptosis, decrease in patho-
genic bacterial adhesion, reduction of pro-inflammatory
cytokines and increase in mucus production and defensin
secretion are some of the mechanisms that are responsible
for the intestinal barrier-preserving effect of probiotic bac-
teria(49). However, at present, no clinical studies in human
subjects have been performed to assess probiotics or pre-
biotics in CD treatment or prevention.
Other emerging therapies involving gluten peptide
modifications and toxicity neutralization
There are other dietary strategies being developed to block
the immune response to gluten based on the identification
of immunogenic epitopes and their suppression via enzy-
matic treatment or by using peptide analogues(50–52).
Gianfrani et al.(51) showed that the transamidation of wheat
flour with microbial transglutaminase can be used to block
the T-cell-mediated gliadin activity. Previously, several
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studies have shown that single amino acid substitution
in the sequence of gliadin T-cell stimulatory peptides
can decrease their binding affinity to the HLA-DQ2 mole-
cule and abolish the immunogenicity of the modified
peptide(53–55). However, the great heterogeneity of toxic
gliadin epitopes is an obstacle against the efficacy of this
immunomodulatory therapy of CD(55). On the other hand,
Kapoerchan et al.(56) have shown that gluten peptides can
be modified at specific positions, for instance introducing
azide functionalities, without affecting their affinity for
HLA-DQ2, and that these constructs can compete with
native gluten peptides and prohibit recognition by HLA-
DQ2-specific T-cells. These antagonist peptides might be a
therapeutic option to treat CD patients as well as prevent
CD development in infants at risk. However, this strategy
would require that these competitive compounds were
administered always accompanying any gluten ingestion,
delivered intact in the small intestine and moreover, they
should have a much higher affinity for the HLA-DQ2
molecule than that of the gliadin-derived peptides. There
could be a different application for these modified peptides
by using them in bread-making dough in substitution for
wheat flour. However, the safest approach seems to be the
enzymatic treatment of gluten with prolyl endopeptidases
from different micro-organisms to detoxify gluten before
reaching the small bowel(57). These enzymes promote
complete digestion of gluten protein preventing antigenic
stimulation of the immune system. However, their stability
under gastric conditions and their efficiency in vivo is still
imprecise(58). In fact, all of these are only emerging
therapies in a developmental stage and no reports of human
trials with these therapies have been published so far.
Conclusion
Dietary strategies to modify environmental determinants
increasing the risk of CD development might be possible
in future. Investigation of these possibilities will require
time and human intervention studies, which could lead
to dietary guidelines that are easily and safely conducted to
prevent the disease.
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